アブストラクト | OBJECTIVES: To conduct a fully independent, external validation of a research study based on one electronic health record database using a different database sampling from the same population. DESIGN: Retrospective cohort analysis of beta-blocker therapy and all-cause mortality in patients with cancer. SETTING: Two UK national primary care databases (PCDs): the Clinical Practice Research Datalink (CPRD) and Doctors' Independent Network (DIN). PARTICIPANTS: CPRD data for 11,302 patients with cancer compared with published results from DIN for 3462 patients; study period January 1997 to December 2006. PRIMARY AND SECONDARY OUTCOME MEASURES: All-cause mortality: overall; by treatment subgroup (beta-blockers only, beta-blockers plus other blood pressure lowering medicines (BPLM), other BPLMs only); and by cancer site. RESULTS: Using CPRD, beta-blocker use was not associated with mortality (HR=1.03, 95% CI 0.93 to 1.14, vs patients prescribed other BPLMs only), but DIN beta-blocker users had significantly higher mortality (HR=1.18, 95% CI 1.04 to 1.33). However, these HRs were not statistically different (p=0.063), but did differ for patients on beta-blockers alone (CPRD=0.94, 95% CI 0.82 to 1.07; DIN=1.37, 95% CI 1.16 to 1.61; p<0.001). Results for individual cancer sites differed by study, but only significantly for prostate and pancreas cancers. Results were robust under sensitivity analyses, but we could not be certain that mortality was identically defined in both databases. CONCLUSIONS: We found a complex pattern of similarities and differences between databases. Overall treatment effect estimates were not statistically different, adding to a growing body of evidence that different UK PCDs produce comparable effect estimates. However, individually the two studies lead to different conclusions regarding the safety of beta-blockers and some subgroup effects differed significantly. Single studies using even internally well-validated databases do not guarantee generalisable results, especially for subgroups, and confirmatory studies using at least one other independent data source are strongly recommended. |
ジャーナル名 | BMJ open |
Pubmed追加日 | 2015/4/15 |
投稿者 | Springate, David A; Ashcroft, Darren M; Kontopantelis, Evangelos; Doran, Tim; Ryan, Ronan; Reeves, David |
組織名 | NIHR School for Primary Care Research, Centre for Primary Care, Institute of;Population, Health, University of Manchester, Manchester, UK Centre for;Biostatistics, Institute of Population Health, University of Manchester,;Manchester, UK.;Centre for Pharmacoepidemiology and Drug Safety, Manchester Pharmacy School,;University of Manchester, Manchester, UK.;Population, Health, University of Manchester, Manchester, UK Centre for Health;Informatics, Institute of Population Health, University of Manchester,;Department of Health Sciences, University of York, York, UK.;Primary Care Clinical Sciences, School of Health and Population Sciences,;University of Birmingham, Edgbaston, UK. |
Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/25869690/ |